RAC

1.11%

$1.83 race oncology ltd

General Comments / Chat, page-5622

First 5622 Last

Share
Profile

Follow
IndexInvestor

8,371 Posts.

1379

16/05/22

15:36

Post #: 61435027
Share

Originally posted by Mason14: ↑

I know I am responding to you directly KB, but this intended more generally: the Israel data is a bit meh for me.

At this point in time, with my small Neanderthal brain, I don't think the data generated will be very attractive to pharma, and I don't think I would be making any investment decisions based on it. This relates specifically to the dose escalation phase and even the expansion. Sure, we could get a CR or even some PR's, but we already know the drug works. And if there are no responses, it won't really mean much to me. This is because the best way to describe this trial is putting a blindfold on and throwing darts (Zantrene) at a dartboard (Patients). We know Zantrene requires a specific patient population. Sure, the team can do a post-hoc biochemical analysis of the patient's tumors that responded, which would give some understanding of why there was a response, but this hardly is demonstrating the 'process' that I have been talking about and that big pharma will want to see.

What I really want to see from a trial is the following:
- Companion diagnostic developed by RAC used to effectively screen participants and select those most likely to respond
- A selection of patients with solid tumors (as opposed to blood tumors) (this is the major limitation I have found with the historic data)
- Peripheral IV formulation of Zantrene developed by RAC (I think the oral formulation is a little while off yet) used either as a single agent and/or in combination with another drug
- Patient responses to the drug are logged, and there are clear links to the companion diagnostic data

This kind of trial demonstrates the full sweep of IP that RAC owns and/or have developed to take Zantrene from a cool drug to a multi-billion dollar asset. If you want Zantrene, you'll have to buy the IP to our companion diagnostic as we as our IV formulation.

Expand

Mason welcome back. I hope you are rested and refreshed.

I agree 99%. BP want to see the whole process including CDx in action.

I don't agree with "We know Zantrene requires a specific patient population". We have a hypothesis that Zantrene will be most effective against cancers with over-expressed FTO. But we don't know that Zantrene will be useless in other cases. Maybe it will be less effective, but better than nothing.
So that could be an interesting outcome of throwing darts blindfolded.

RAC Price at posting: $1.88 Sentiment: Buy Disclosure: Held
23 Upvote

3 Great analysis

Reply

Top Stories

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

RCE

Recce's R327 found effective against E.coli during clinical trial

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Microcap Wrap: 5 explorers with news out today

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

There are more pages in this discussion • 5,402 more messages in this thread...

First 5622 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.83		Change 0.020(1.11%)		Mkt cap ! $310.7M

Open	High	Low	Value	Volume
$1.81	$1.83	$1.79	$142.0K	78.77K

Buyers (Bids)

No.	Vol.	Price($)
1	500	$1.81

Sellers (Offers)

Price($)	Vol.	No.
$1.83	641	1

View Market Depth

No.	Vol.	Price($)
1	500	1.810
3	7009	1.790
1	450	1.780
1	651	1.775
3	17043	1.770

Price($)	Vol.	No.
1.825	641	1
1.830	1209	2
1.835	651	1
1.840	4651	3
1.845	2746	1

Last trade - 16.10pm 28/06/2024 (20 minute delay)

RAC (ASX) Chart

General Comments / Chat, page-5622

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Recce's R327 found effective against E.coli during clinical trial

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Ava Risk Group expands US presence with A$0.7M Substation Deal

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Microcap Wrap: 5 explorers with news out today

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

General Comments / Chat, page-5622

Top Stories

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Recce's R327 found effective against E.coli during clinical trial

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Ava Risk Group expands US presence with A$0.7M Substation Deal

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Microcap Wrap: 5 explorers with news out today

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News